Longwood Healthcare Leaders 春季会议以麻省理工学院Koch研究所为中心，通过网络会议邀请生物制药公司的首席执行官、研发负责人、及顶级学术研究人员参加，共同商讨，促进药物研发的转化，造福病人！会议由诺贝尔奖获得者，Biogen/Alnylam 联合创始人 Phil Sharp 共同主持。会议仅限受邀参加。
Longwood Healthcare Leaders Spring Meeting centered on MIT’s Koch Institute via web-conference with leading bio-pharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp. Longwood Healthcare Leaders Meetings drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients. Meetings are invitation-only.
Panel Discussion
美迪西创始人兼CEO陈春麟博士将参加此次大会，并在5月4日上午 9:50 （美东时间）与 Raj Devraj (Rectify Pharmaceuticals公司CEO), Bill Hinshaw (Axcella Therapeutics 公司CEO), Peter Lebowitz (Janssen 全球肿瘤治疗领域负责人), Reenie McCarthy (Stealth BioTherapeutics 公司CEO)， Chen Schor (Adicet Bio 公司CEO)一起进行嘉宾讨论，主题为“Expediting Research for Treatment and Cures”。
Dr. Chun-Lin Chen, founder & CEO of Medicilon, will participate in the panel discussion titled "Expediting Research for Treatment and Cures" on May 4 at 9:50 am ET. The other invited participants are Raj Devraj (CEO, Rectify Pharmaceuticals), Bill Hinshaw (CEO, Axcella Therapeutics), Peter Lebowitz (Global Oncology Therapeutic Area Head, Janssen), and Reenie McCarthy (CEO, Stealth BioTherapeutics). The panel discussion is moderated by Chen Schor (CEO, Adicet Bio).
Garden Party
陈春麟博士、美国商务发展副总裁 Stephen Grant及美国商务团队将于 5 月 5 日下午 5:00-7:00（美东时间）参加 Garden Party。届时将与参会的众嘉宾进行详细交谈，共同探讨我们的专业服务如何更快地加速各企业的药物研发过程！
Dr. Chun-Lin Chen and Medicilon VP of US Business Development Dr. Stephen Grant together with our US Business Development team will be joining the Garden Party on MAY 5 at 5:00-7:00 pm ET. We are looking forward to meeting you in this party to discuss how our services and capabilities would support your research needs and expedite your drug discovery and development programs. Wish you a safe trip!
About Medicilon
美迪西是一家专业的生物医药临床前综合研发服务CRO，为全球的医药企业和科研机构提供全方位的符合国内及国际申报标准的一站式新药研发服务。我们关注全球医药行业创新发展的需求，立足于创新药物研发的关键环节，凭借服务国内外生物医药行业所积累的经验，构建涵盖药物发现、药学研究以及临床前研究关键技术的综合性技术平台，为全球生物医药行业提供全方位新药临床前研发服务。至2021年报告期末，美迪西已为全球超过1460家客户提供新药研发服务，参与研发完成的新药项目有221件IND获批临床，与国内外优质客户共同成长。美迪西将继续立足全球视野，聚力中国创新，为人类健康贡献力量！
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.
18+
18+ years of experience in new drug R&D
18+年新药研发经验
1460+
Active clients worldwide
全球范围内活跃客户
2440+
Newdrug discovery scientists and service personnel新药研发科学家及研发服务人员
74000+
Square meters of Laboratory floor space
研发实验室
221
Projects successfully approved with NMPA, FDA, EMA, and TGA
221件IND在 NMPA、FDA、EMA 和 TGA 成功获批
联系我们：
电话: +86 (21) 5859-1500（总机）
相关新闻
